Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study

Objective. To determine the prevalence and risk factors for the recurrence of retinopathy of prematurity (ROP) in Zone II Stage 3+ after ranibizumab treatment. Methods. This was a retrospective, nonrandomized, noncontrolled study that excluded Zone I and aggressive posterior ROP (APROP) cases. Infan...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Qinrui, Bai, Yujing, Chen, Xiaoli, Huang, Lvzhen, Chen, Yi, Li, Xiaoxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401749/
https://www.ncbi.nlm.nih.gov/pubmed/28491468
http://dx.doi.org/10.1155/2017/5078565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401749/
https://www.ncbi.nlm.nih.gov/pubmed/28491468
http://dx.doi.org/10.1155/2017/5078565

Ejemplares similares